KL
Kalaris Therapeutics Inc
KLRS · NASDAQ
$3.16 -0.63% (-$0.02)
1M -21.95%
Market Cap $69.0M
P/E Ratio -
Div. Yield -
ROE 71.71%
Bulios Fair Price
$1.82
42.4% downside
Current Price
$3.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KLRS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
0/9Valuation
100 /100
Cheap P/B 1.20x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 52.40%
ROE 71.71%
ROA 44.47%
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 10.98x
Int. coverage N/A
Stability
29 /100
Unstable Beta 0.21x
EPS volatility 32.99%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KLRS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew Oxtoby
Employees
20
Headquarters
Berkeley Heights
Upcoming events
11 NOV
Earnings
Upcoming earnings report